TrialThe Lancet. Oncology2016

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

Marcia S Brose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.